Radiation-Induced Pulmonary Fibrosis: Roles of Therapy-Induced Senescence and microRNAs
CONCLUSION: Our analysis of the published literature in the last decade on RIPF, miRNA, and TIS identifies TIS as a mechanism in the onset and progression of RIPF, which is regulated through several miRNAs. This work may lead to the discovery and development of the next generation of miRNA therapeutics and/or the repurposing of approved pharmaceutical agents and the development of early biomarker panels to predict RIPF.PMID:36763093 | DOI:10.1080/09553002.2023.2177768 (Source: International Journal of Radiation Biology)
Source: International Journal of Radiation Biology - February 10, 2023 Category: Radiology Authors: Pataje G S Prasanna Molykutty Aryankalayil Deborah E Citrin C Norman Coleman Source Type: research
COVID ‐19: Understanding the impact of anti‐hypertensive drugs and hydroxychloroquine on the ACE1 and ACE2 in lung and adipose tissue in SHR and WKY rats
Losartan treatment decreased ACE2 in tissues, mainly in male than female SHR; captopril treatment showed decreased ACE2 in lung tissue of females and both sexes SHR in the adipose tissue. Hydroxychloroquine effectively decreased ACE2 in the lung of both sexes SHR and only in females WKY. And in the adipose tissue, hydroxychloroquine decreased ACE2 in male SHR and female WKY. AbstractHypertensive individuals taking anti-hypertensive drugs from renin-angiotensin system inhibitors may exhibit a more severe evolution of the disease when contracting the SARS-CoV-2 virus (COVID-19 disease) due to potential increases in ACE2 expr...
Source: Physiological Reports - February 7, 2023 Category: Physiology Authors: Beatriz Santos Geoffroy Corr êa,
Silvana Barros,
Julia Braga Vaz,
Maria Angelica Peres,
Mayara Klimuk Uchiyama,
Alexandre Alves Silva,
Luzia Naoko Shinohara Furukawa Tags: ORIGINAL ARTICLE Source Type: research
Topical Captopril: A Promising Treatment for Secondary Lymphedema
Transl Res. 2023 Feb 1:S1931-5244(23)00017-8. doi: 10.1016/j.trsl.2023.01.005. Online ahead of print.ABSTRACTTransforming growth factor-beta 1 (TGF-β1)-mediated tissue fibrosis is an important regulator of lymphatic dysfunction in secondary lymphedema. However, TGF-β1 targeting can cause toxicity and autoimmune complications, limiting clinical utility. Angiotensin II (Ang II) modulates intracellular TGF-β1 signaling, and inhibition of Ang II production using angiotensin-converting enzyme (ACE) inhibitors, such as captopril, has antifibrotic efficacy in some pathological settings. Therefore, we analyzed the expression of...
Source: Translational Research : the journal of laboratory and clinical medicine - February 3, 2023 Category: Laboratory Medicine Authors: Stav Brown Gabriela D Garc ía Nores Ananta Sarker Catherine Ly Catherine C Li Hyeung Ju Park Geoffrey E Hespe Adana Campbell Raghu P Kataru Omer Aras Babak J Mehrara Source Type: research
Topical Captopril: A Promising Treatment for Secondary Lymphedema
Transl Res. 2023 Feb 1:S1931-5244(23)00017-8. doi: 10.1016/j.trsl.2023.01.005. Online ahead of print.ABSTRACTTransforming growth factor-beta 1 (TGF-β1)-mediated tissue fibrosis is an important regulator of lymphatic dysfunction in secondary lymphedema. However, TGF-β1 targeting can cause toxicity and autoimmune complications, limiting clinical utility. Angiotensin II (Ang II) modulates intracellular TGF-β1 signaling, and inhibition of Ang II production using angiotensin-converting enzyme (ACE) inhibitors, such as captopril, has antifibrotic efficacy in some pathological settings. Therefore, we analyzed the expression of...
Source: Cell Research - February 3, 2023 Category: Cytology Authors: Stav Brown Gabriela D Garc ía Nores Ananta Sarker Catherine Ly Catherine C Li Hyeung Ju Park Geoffrey E Hespe Adana Campbell Raghu P Kataru Omer Aras Babak J Mehrara Source Type: research
Topical Captopril: A Promising Treatment for Secondary Lymphedema
Transl Res. 2023 Feb 1:S1931-5244(23)00017-8. doi: 10.1016/j.trsl.2023.01.005. Online ahead of print.ABSTRACTTransforming growth factor-beta 1 (TGF-β1)-mediated tissue fibrosis is an important regulator of lymphatic dysfunction in secondary lymphedema. However, TGF-β1 targeting can cause toxicity and autoimmune complications, limiting clinical utility. Angiotensin II (Ang II) modulates intracellular TGF-β1 signaling, and inhibition of Ang II production using angiotensin-converting enzyme (ACE) inhibitors, such as captopril, has antifibrotic efficacy in some pathological settings. Therefore, we analyzed the expression of...
Source: Translational Research : the journal of laboratory and clinical medicine - February 3, 2023 Category: Laboratory Medicine Authors: Stav Brown Gabriela D Garc ía Nores Ananta Sarker Catherine Ly Catherine C Li Hyeung Ju Park Geoffrey E Hespe Adana Campbell Raghu P Kataru Omer Aras Babak J Mehrara Source Type: research
Topical Captopril: A Promising Treatment for Secondary Lymphedema
Transl Res. 2023 Feb 1:S1931-5244(23)00017-8. doi: 10.1016/j.trsl.2023.01.005. Online ahead of print.ABSTRACTTransforming growth factor-beta 1 (TGF-β1)-mediated tissue fibrosis is an important regulator of lymphatic dysfunction in secondary lymphedema. However, TGF-β1 targeting can cause toxicity and autoimmune complications, limiting clinical utility. Angiotensin II (Ang II) modulates intracellular TGF-β1 signaling, and inhibition of Ang II production using angiotensin-converting enzyme (ACE) inhibitors, such as captopril, has antifibrotic efficacy in some pathological settings. Therefore, we analyzed the expression of...
Source: Translational Research : the journal of laboratory and clinical medicine - February 3, 2023 Category: Laboratory Medicine Authors: Stav Brown Gabriela D Garc ía Nores Ananta Sarker Catherine Ly Catherine C Li Hyeung Ju Park Geoffrey E Hespe Adana Campbell Raghu P Kataru Omer Aras Babak J Mehrara Source Type: research
